Organon (OGN) Other Working Capital Changes (2020 - 2026)
Organon (OGN) posted quarterly Other Working Capital Changes of -$8.0 million for Q1 2026, down 172.73% year-over-year from $11.0 million in Q1 2025, and up 20.0% on a QoQ basis from -$10.0 million in Q4 2025.
Organon (OGN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Other Working Capital Changes for 7 consecutive years, with -$8.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 172.73% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$158.0 million (down 4050.0% YoY), while the FY2025 annual figure was -$139.0 million, down 379.31% from the prior year.
- Other Working Capital Changes came in at -$8.0 million for Q1 2026 at Organon, up from -$10.0 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $178.0 million in Q2 2024, with the low at -$223.0 million in Q3 2024.
- Average Other Working Capital Changes over 5 years is -$11.5 million, with a median of -$8.0 million recorded in 2025.
- The largest YoY upside for Other Working Capital Changes was 584.62% in 2024 against a maximum downside of 555.1% in 2024.
- Year by year, Other Working Capital Changes stood at $16.0 million in 2022, then tumbled by 550.0% to -$72.0 million in 2023, then jumped by 152.78% to $38.0 million in 2024, then sank by 126.32% to -$10.0 million in 2025, then grew by 20.0% to -$8.0 million in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$8.0 million, -$10.0 million, and -$8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -10.00 Mn |
| Dec 31, 2025 | -10.00 Mn |
| Dec 31, 2025 | -10.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Jun 30, 2025 | -132.00 Mn |
| Jun 30, 2025 | -132.00 Mn |
| Jun 30, 2025 | -132.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Dec 31, 2024 | 38.00 Mn |
| Dec 31, 2024 | 38.00 Mn |
| Dec 31, 2024 | 38.00 Mn |
| Sep 30, 2024 | -223.00 Mn |
| Sep 30, 2024 | -223.00 Mn |